Free tool
FAERS Monitor: Camcevi Kit
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211488 or its brand name (Camcevi Kit, Leuprolide Mesylate). Reports on generic versions are filed under their own applications.
Reports
1,595
Serious
1,120
70% of reports
Hospitalization
522
Death reported
132
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective118
- fatigue99
- off label use90
- nausea79
- headache69
- malignant neoplasm progression62
- disease progression57
- vomiting49
- febrile neutropenia48
- product storage error45
- hot flush44
- product use in unapproved indication41
- anaemia39
- dyspnoea39
- pain39
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 2 |
| 2006 | 3 |
| 2011 | 6 |
| 2012 | 7 |
| 2013 | 27 |
| 2014 | 31 |
| 2015 | 31 |
| 2016 | 30 |
| 2017 | 62 |
| 2018 | 94 |
| 2019 | 151 |
| 2020 | 126 |
| 2021 | 140 |
| 2022 | 126 |
| 2023 | 140 |
| 2024 | 159 |
| 2025 | 250 |
| 2026 | 210 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,564 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 48 | 9.5 | 7.2 | 360 |
| malignant neoplasm progressionSignal | 62 | 8.0 | 6.3 | 374 |
| hot flushSignal | 44 | 7.7 | 5.8 | 251 |
| product storage errorSignal | 45 | 6.8 | 5.1 | 217 |
| disease progressionSignal | 57 | 6.4 | 4.9 | 253 |
| anaemiaSignal | 39 | 2.7 | 2.0 | 40 |
| product use in unapproved indicationSignal | 41 | 2.2 | 1.6 | 25 |
| fatigue | 99 | 1.7 | 1.4 | 27 |
| headache | 69 | 1.5 | 1.2 | 10 |
| vomiting | 49 | 1.4 | 1.0 | 5 |
| off label use | 90 | 1.4 | 1.1 | 8 |
| nausea | 79 | 1.3 | 1.1 | 6 |
| drug ineffective | 118 | 1.2 | 1.0 | 3 |
| dyspnoea | 39 | 0.9 | 0.7 | 0 |
| pain | 39 | 0.8 | 0.6 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.